Journal of Dermatological Treatment (Dec 2024)
Comparative effectiveness of tildrakizumab 200 mg versus tildrakizumab 100 mg in psoriatic patients with high disease burden or above 90 kg of body weight: a 16-week multicenter retrospective study – IL PSO (Italian landscape psoriasis)
- Luigi Gargiulo,
- Luciano Ibba,
- Ruggero Cascio Ingurgio,
- Piergiorgio Malagoli,
- Fabrizio Amoruso,
- Anna Balato,
- Federico Bardazzi,
- Pina Brianti,
- Giovanna Brunasso,
- Martina Burlando,
- Anna E. Cagni,
- Marzia Caproni,
- Carlo G. Carrera,
- Andrea Carugno,
- Francesco Caudullo,
- Aldo Cuccia,
- Paolo Dapavo,
- Eugenia V. Di Brizzi,
- Valentina Dini,
- Francesca M. Gaiani,
- Paolo Gisondi,
- Claudio Guarneri,
- Claudia Lasagni,
- Gaetano Licata,
- Francesco Loconsole,
- Angelo V. Marzano,
- Matteo Megna,
- Santo R. Mercuri,
- Maria L. Musumeci,
- Diego Orsini,
- Simone Ribero,
- Valentina Ruffo Di Calabria,
- Francesca Satolli,
- Davide Strippoli,
- Massimo Travaglini,
- Emanuele Trovato,
- Marina Venturini,
- Leonardo Zichichi,
- Mario Valenti,
- Antonio Costanzo,
- Alessandra Narcisi
Affiliations
- Luigi Gargiulo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Luciano Ibba
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Ruggero Cascio Ingurgio
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Piergiorgio Malagoli
- Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy
- Fabrizio Amoruso
- Dermatology Unit, Azienda Ospedaliera di Cosenza, Cosenza, Italy
- Anna Balato
- Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
- Federico Bardazzi
- Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
- Pina Brianti
- Dermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, Italy
- Giovanna Brunasso
- Dermatology Department, Galliera Hospital, Genoa, Italy
- Martina Burlando
- Department of Dermatology, Dipartimento di Scienze della Salute (DISSAL), University of Genoa, IRCCS Ospedale Policlinico San Martino, Genoa, Italy
- Anna E. Cagni
- Unità Operativa Dipartimentale di Dermatologia e Venereologia, IRCCS San Gerardo, Milan, Italy
- Marzia Caproni
- Immunopathology and Rare Skin Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda Unità Sanitaria Locale Toscana Centro, University of Florence, Florence, Italy
- Carlo G. Carrera
- Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Andrea Carugno
- Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Bergamo, Italy
- Francesco Caudullo
- Dermatology Clinic, University of Catania, Catania, Italy
- Aldo Cuccia
- Unit of Dermatology, San Donato Hospital, Arezzo, Italy
- Paolo Dapavo
- Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy
- Eugenia V. Di Brizzi
- Dermatology Unit, University of Campania L. Vanvitelli, Naples, Italy
- Valentina Dini
- Department of Dermatology, University of Pisa, Pisa, Italy
- Francesca M. Gaiani
- Department of Dermatology, Dermatology Unit Azienda Ospedaliera San Donato Milanese, Milan, Italy
- Paolo Gisondi
- University of Verona, Verona, Italy
- Claudio Guarneri
- Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
- Claudia Lasagni
- Dermatological Clinic, Department of Specialized Medicine, University of Modena, Modena, Italy
- Gaetano Licata
- U.O.C. Dermatology Unit, "S. Antonio Abate" Hospital, Trapani, Italy
- Francesco Loconsole
- Department of Dermatology, University of Bari, Bari, Italy
- Angelo V. Marzano
- Dermatology Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
- Matteo Megna
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
- Santo R. Mercuri
- Dermatology and Cosmetology Unit, IRCCS San Raffaele Hospital, Milan, Italy
- Maria L. Musumeci
- Dermatology Clinic, University of Catania, Catania, Italy
- Diego Orsini
- UOC Clinical Dermatology, Dermatological Institute S. Gallicano, IRCCS, Rome, Italy
- Simone Ribero
- Department of Biomedical Science and Human Oncology, Second Dermatologic Clinic, University of Turin, Turin, Italy
- Valentina Ruffo Di Calabria
- Immunopathology and Rare Skin Diseases Unit, Section of Dermatology, Department of Health Sciences, Azienda Unità Sanitaria Locale Toscana Centro, University of Florence, Florence, Italy
- Francesca Satolli
- Unit of Dermatology, University of Parma, Parma, Italy
- Davide Strippoli
- Dermatology Unit, ASST Lecco, Alessandro Manzoni Hospital, Lecco, Italy
- Massimo Travaglini
- U.O.S.D. dermatologica – centro per la cura della psoriasi, Ospedale Perrino, Brindisi, Italy
- Emanuele Trovato
- Unit of Dermatology, Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy
- Marina Venturini
- Dermatology Department, University of Brescia, ASST Spedali Civili of Brescia, Brescia, Italy
- Leonardo Zichichi
- U.O.C. Dermatology Unit, "S. Antonio Abate" Hospital, Trapani, Italy
- Mario Valenti
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Antonio Costanzo
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- Alessandra Narcisi
- Dermatology Unit, IRCCS Humanitas Research Hospital, Rozzano, Italy
- DOI
- https://doi.org/10.1080/09546634.2024.2350760
- Journal volume & issue
-
Vol. 35,
no. 1
Abstract
Purpose Tildrakizumab is a selective inhibitor of IL-23 approved for the treatment of moderate-to-severe plaque psoriasis in two dosages. We conducted a 16-week multicenter retrospective study to compare the effectiveness and safety of tildrakizumab 200 mg versus tildrakizumab 100 mg in patients with a high disease burden or high body weight.Materials and methods Our retrospective study included 134 patients treated with tildrakizumab 200 mg and 364 patients treated with tildrakizumab 100 mg from 28 Italian Dermatology Units affected by moderate-to-severe plaque psoriasis. The patients had a body weight above 90 kg or a high disease burden (Psoriasis Area and Severity Index [PASI] ≥ 16 or the involvement of difficult-to-treat areas). We evaluated the effectiveness of tildrakizumab at the week-16 visit in terms of PASI90, PASI100 and absolute PASI ≤ 2.Results After 16 weeks of treatment with tildrakizumab 200 mg, PASI90 was reached by 57.5% of patients and PASI100 by 39.6% of patients. At the same time point, 34.3% and 24.2% of patients treated with tildrakizumab 100 mg achieved PASI90 and PASI100, respectively.Conclusions Our data suggest that tildrakizumab 200 mg has better effectiveness than tildrakizumab 100 mg in patients with a body weight ≥ 90 kg and a high disease burden.
Keywords
